Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.

32 Though there is a critical need for novel therapies in this treatment space, the initial FDA approved dose and schedule of selinexor proved difficult in the clinical setting with fairly significant gastrointestinal toxicity including nausea, anorexia and weight loss.

also in 581 other papers